Numerous etiological studies have established a positive clinical association between hypertension and erectile dysfunction. However, to date, the mechanism underlying this dysfunction remains to be established. In this study, we demonstrate the presence of erectile dysfunction in two rat models of hypertension, and hypothesize that increased vasoconstrictor signaling via Rhokinase contributes to the decreased erectile response. We found deoxycorticosterone-salt and stroke prone-spontaneously hypertensive rats to exhibit a decreased erectile response, recorded as intracavernosal pressure=mean arterial pressure (ICP=MAP) upon electrical stimulation of the major pelvic ganglion. As previously shown, inhibition of Rho-kinase activity by intracavernosal injection of the selective inhibitor, Y-27632, resulted in an increase in ICP=MAP. However, Y-27632 was significantly less effective at increasing ICP=MAP in the hypertensive as compared to normotensive rats. Additionally, intracavernosal injection of Y-27632 potentiated the voltagestimulated increase in ICP=MAP in both hypertensive and normotensive rats, but was less effective at potentiating the voltage-mediated erectile response in the hypertensive rats. Altogether, our data demonstrate a decreased erectile response in a mineralocorticoid and genetic model of hypertension, and suggest the role of increased cell signaling by Rho-kinase in the vasoconstrictor activity of erectile dysfunction associated with hypertension.
Introduction
Hypertension is associated with increased vasoconstrictor and reduced vasodilatory responses and vascular remodeling. [1] [2] [3] The pathological changes resulting from altered vascular functioning include injury to the brain, kidney and heart. Various studies have established a clinical correlation between incidence of hypertension and erectile dysfunction. Although some cases of erectile dysfunction are the result of arterial injury, drug sideeffects and depression, many have their roots in vascular abnormalities such as those associated with hypertension.
Unlike blood vessels in other vascular beds, the cavernosal vasculature is composed of a network of connective tissue that surrounds sinuses lined with smooth muscle and endothelial cells. The intracavernosal pressure which mediates the state of erection, is regulated by the smooth muscle and endothelial cells lining the cavernosal arterioles and sinuses. The penis is normally maintained in a flaccid state by cavernosal vasoconstriction which minimizes intracavernosal blood flow and pressure (ICP). Activation of non-adrenergic=non-cholinergic nerves releases nitric oxide, initiating cavernosal smooth muscle relaxation to result ultimately in increased ICP. [4] [5] [6] The initial rise in ICP activates a pressure-dependent veno-occlusive mechanism to limit the outflow of blood, thus further promoting elevated ICP and the erectile response. The increased blood flow is ultimately driven, therefore, by the force of the arterial blood pressure. 7 Although this nitric oxide-mediated pathway is thought to be the principal mechanism leading to erection, evidence also exists implicating the role of other vasodilators (acetylcholine 4, 6 and vasoactive intestinal peptide, [8] [9] [10] as well as various vasoconstrictors (norepinephrine [11] [12] [13] and endothelin-1 [14] [15] [16] ), in the regulation of cavernosal tone. We have recently established the importance of the Rho-kinasemediated vasoconstrictor pathway in the maintenance of penile flaccidity, demonstrating the intracavernosal injection of a selective Rho-kinase inhibitor, Y-27632, to induce an erectile response, independent of nitric oxide stimulation. 17, 18 Rho-kinase is one downstream target of the small GTPase, RhoA. Activity of the RhoA=Rho-kinase pathway is involved in the calcium-sensitization of smooth muscle cells. 19 Rho-kinase is known to promote contraction via inhibition of phosphatase activity leading to the maintenance of phosphorylation of myosin light chain. 20, 21 Additionally, Rhokinase has been shown in solution to directly phosphorylate myosin light chain (MLC). 22 The inhibition of Rho-kinase by Y-27632 results in the relaxation of various isolated vascular segments constricted with GTPgS or agonists such as phenylephrine, serotonin and endothelin, but not of depolarization-induced contraction.
Recent evidence from our lab and others has shown Rho-kinase constrictor activity to be elevated in the vasculature from various animal models hypertension. 1, [23] [24] [25] Uehata et al found per os treatment with Y-27632 to result in a significant decrease in blood pressure in hypertensive, but not normotensive, rats. 23 Additionally, pre-contracted (with phenylephrine or serotonin) endothelium denuded mesenteric arteries from mineralocorticoid or angiotensin-II treated rats displayed an increase in vasodilator sensitivity to Y-27632. 1, 24 An increase in vascular Rho-kinase activity in hypertension suggests a possible mechanism by which hypertension may correlate with a decreased erectile response. In this study, we establish the presence of a decreased erectile response in hypertensive rats, and hypothesize that this dysfunction is mediated by increased Rho-kinase activity in the cavernosal arterioles and sinus governing the regulation of the erectile state.
Methods

In vivo measurements of ICP=MAP
The left carotid artery and right corpus cavernosum of the rat penis were cannulated for continuous monitoring of mean arterial pressure (MAP) and ICP respectively (as previously described). 26 Vasoactive drugs were administered through a cannula in the left corpus cavernosum. For experiments measuring voltage-stimulated changes in ICP and MAP, stainless steel bipolar electrodes were positioned on the right major pelvic ganglion. In order to examine the effects of ganglionic stimulation on ICP=MAP, the major pelvic ganglion was stimulated with various voltages (1-5 v, 5 ms pulses at a frequency of 12 Hz). In experiments examining the role of Rho-kinase, the selective inhibitor, Y-27632 (50 nmol) was administered by intracavernosal injection. In further experiments, voltage stimulation was repeated after the response to Y-27632 had reached a plateau.
Animals and drugs
Male Sprague-Dawley rats (200-250 g; Harlan) were made hypertensive by uninephrectomy and implantation of a deoxycorticosterone-acetate (DOCA) silastic pellet at the back of the neck. DOCA rats received salt-water (1% NaCl, 0.2% KCl) for 4 weeks. Sham control rats were uninephrectomized and drank tap water. Male stroke prone-spontaneously hypertensive rats (SHRSP) (12 weeks old, 350 g) were obtained from the breeding colony at the Medical College of Georgia, Augusta, GA, USA. Systolic blood pressures were taken by tail cuff measurement (DOCA=sham: after 4 weeks treatment; SHRSP: at 12 weeks of age). For in vivo experiments, rats were anesthetized with ketamine (87 mg=kg body weight) þ xylazine (13 mg=kg body weight) and maintained on supplemental ketamine as needed. All rats were housed according to guidelines at the Medical College of Georgia. DOCA was purchased from Sigma Corporation. Y-27632 was a gracious gift from Welfide Corporation, Osaka, Japan.
Statistics
Data expressed as means AE standard error of the mean, and analyzed using ANOVA with StudentNewman-Keuls post-hoc analysis (P ¼ 0.05, DOCA compared to sham and SHRSP compared to Sprague-Dawley control).
Results
Blood pressure measurements DOCA-treated rats (4 weeks of treatment) and SHRSP (12 weeks of age) exhibited a significantly increased systolic blood pressure as compared to sham and normotensive Sprague-Dawley rats, respectively (DOCA (n ¼ 13) and SHRSP (n ¼ 4) systolic blood pressures > 170 mmHg, sham (n ¼ 11) and Sprague-Dawley (n ¼ 18) systolic blood pressures < 130 mmHg).
Effect of voltage stimulation of the major pelvic ganglion on ICP=MAP
To examine the effect of ganglionic-mediated increases in ICP=MAP, the major pelvic ganglion was (Figure 1 ). 14 The increase in ICP=MAP upon ganglionic stimulation was decreased in DOCA and SHRSP rats compared to sham and normotensive control rats, respectively, at each voltage ( Figure 1 ).
Effect of Y-27632 on ICP=MAP
We have previously established the importance of Rho-kinase in the maintenance of cavernosal vasoconstriction. We therefore sought to examine the effect of Rho-kinase inhibition on the erectile response in hypertensive rats, hypothesizing that an increase in Rho-kinase activity contributes to the decreased erectile function. Injection of the selective Rho-kinase antagonist, Y-27632 (50 nmol) into the left corpus cavernosum sinuses resulted in a significant increase in ICP=MAP, in accordance with our previously published findings. 17 In this study, we found intracavernosal injection of Y-27632 to have no significant effect on MAP in sham and normotensive control Sprague-Dawley rats, but to significantly decrease MAP in SHRSP, consistent with the original findings of Ueheta et al (1997) (MAP (following anesthesia, mmHg) before and after Y-27632 respectively: DOCA 122 AE 7.3 to 110 AE 5.5, sham 108 AE 7.1 to 99 AE 5.8; *SHRSP 123 AE 9.0 to 109 AE 4.6, control 91 AE 2.3 to 82 AE 2.0; *P < 0.05; n ¼ 5-19 per group). The elevation in ICP=MAP resulting from intracavernosal injection of Y-27632 was significantly decreased in DOCA vs sham rats, as well as in SHRSP vs normotensive SpragueDawley rats (Figure 2 ).
Effect of Y-27632 on voltage-mediated increases in ICP=MAP
We next examined the effect of Y-27632 on the voltage-induced increase in ICP=MAP. Y-27632 (50 nmol=kg) was injected into the left corpus cavernosum and the increased ICP response allowed to plateau. Subsequently, the ICP=MAP response to ganglionic stimulation was assessed over a range of voltages (1-5 v) . The increase in ICP=MAP following the administration of Y-27632 was significantly less in the DOCA and SHRSP, as compared to the sham and normotensive controls, respectively (Figure 3 ).
Discussion
The findings of this study demonstrate decreased erectile function in two rat models of hypertension, Decreased erectile response in hypertension K Chitaley et al supporting clinical studies linking hypertension and erectile dysfunction. Further, these data implicate an increase in Rho-kinase activity as a possible mechanism underlying the decreased erectile function. Previous studies have found a significant suppression of ganglionic-induced increases in ICP=MAP in the presence of various inhibitors of nitric oxide synthase, suggesting a major component of the voltage-mediated response is due to nitric oxide release. 27, 28 Voltage stimulation of the major pelvic ganglion induced an increase in ICP=MAP, which was significantly suppressed in DOCA and SHRSP rats, compared to sham and normotensive Sprague-Dawley rats, respectively ( Figure 1) . Interestingly, dysfunctional endothelium-dependent vasodilator responses have been demonstrated in the vasculature of various hypertensive animal models. 2 However, endothelial abnormalities associated with hypertension may not fully explain the mechanism for the decreased erectile response in hypertensive rat models. A large part of nitric oxide release during erection is thought to be generated by neuronal nitric oxide synthase (nNOS) through the stimulation of the nonadrenergic, noncholinergic nerves to the corpus cavernosum. In fact, endothelial nitric oxide synthase (eNOS) deficient mice retain their fertility, suggesting eNOS is not solely responsible for nitric oxide generation during erection. 29 However, an up-regulation in cavernosal eNOS was demonstrated in nNOS deficient mice (intact erectile response), in fact suggesting a compensatory, sufficient, role of eNOS in erectile stimulation. 30 Although the exact role of nNOS and eNOS in the penile vasculature are not yet detailed, it is apparent that dysfunctional eNOS associated with hypertension is not the sole mechanism underlying the concurrent erectile dysfunction.
We recently demonstrated the importance of the vasoconstriction-promoting enzyme, Rho-kinase, in the maintenance of penile flaccidity and found that the selective pharmacologic inhibition of Rhokinase results in a sustained increase in ICP=MAP. Additionally, data from our lab and others suggest an increase in Rho-kinase activity in the vasculature of various hypertensive animal models. 1, [23] [24] [25] We hypothesized, therefore, that an increase in cavernosal Rho-kinase activity contributes to the erectile dysfunction seen in DOCA and SHRSP. Intracavernosal injection of the selective inhibitor of Rho-kinase 23, 31 Y-27632 (50 nmol), resulted in an increase in ICP=MAP, however this effect was significantly suppressed in the hypertensive rats ( Figure 2) . As previously shown, we found treatment with Y-27632 to potentiate the ganglionicmediated increase in ICP=MAP. However, 50 nmol of Y-27632 was less effective at increasing the ICP=MAP response to ganglionic stimulation in the DOCA and SHRSP, suggesting an increase in Rhokinase activity in the cavernosum of hypertensive rats (Figure 3) .
Many investigators report a high prevalence of erectile dysfunction among hypertensive men. It is also known that drugs used to treat hypertension can cause erectile dysfunction. Hypertension is characterized by increased peripheral vascular resistance along with reduced nitric oxide bioavailability, both of which favor a reduction in the erectile response. Diuretics and b-blockers appear to cause the greatest degree of erectile dysfunction, with lesser problems among men who take aantagonists, ACE inhibitors, angiotensin-II receptor antagonists and calcium channel blockers. 32, 33 The primary reason men quit taking medication for high blood pressure is the problem of impotence. It is tempting to speculate that Rho-kinase inhibition may be a potential treatment for hypertension, circumventing the deleterious effects on the erectile response. Treatment of various rat models with the Rho-kinase antagonist, Y-27632, has been shown to significantly decrease blood pressure in hypertensive, but not normotensive, rats. 23 This study as well as our previously published results indicate that Decreased erectile response in hypertension K Chitaley et al treatment with Y-27632 increases erectile function in the various rat models, suggesting a beneficial, and not deleterious effect of Y-27632 on the erectile tissue. Altogether, our data support clinical appraisals linking hypertension and the presence of erectile dysfunction, and suggest a possible mechanism mediating the decreased erectile response.
